5 results match your criteria: "Rivoli Infermi Hospital ASLTO3[Affiliation]"
Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction With or Without ST-Segment Elevation.
J Am Coll Cardiol
November 2024
Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy.
Background: The effectiveness of complete revascularization is well established in patients with ST-segment elevation myocardial infarction (STEMI), but it is less investigated in those with non-ST-segment elevation myocardial infarction (NSTEMI).
Objectives: This study aimed to assess whether complete revascularization, compared with culprit-only revascularization, was associated with consistent outcomes in older patients with STEMI and NSTEMI.
Methods: In the FIRE (Functional Assessment in Elderly MI Patients with Multivessel Disease) trial, 1,445 older patients with myocardial infarction (MI) were randomized to culprit-only or physiology-guided complete revascularization, stratified by STEMI (n = 256 culprit-only vs n = 253 complete) and NSTEMI (n = 469 culprit-only vs n = 467 complete).
Health-Status Outcomes in Older Patients With Myocardial Infarction: Physiology-Guided Complete Revascularization Versus Culprit-Only Strategy.
Circ Cardiovasc Qual Outcomes
July 2024
Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Italy (G. Campo, S.B.).
Background: The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) enrolled 1445 older (aged ≥75 years) patients with myocardial infarction and multivessel disease in Italy, Spain, and Poland. Patients were randomized to physiology-guided complete revascularization or treatment of the only culprit lesion. Physiology-guided complete revascularization significantly reduced ischemic adverse events at 1 year.
View Article and Find Full Text PDFComplete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk: A Randomized Clinical Trial.
JAMA Cardiol
June 2024
Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy.
Article Synopsis
- Patients with high bleeding risk (HBR) following a myocardial infarction (MI) face poor outcomes, and it's uncertain if they benefit from complete revascularization.
- The study aimed to compare the outcomes of physiology-guided complete revascularization versus a culprit-only strategy for HBR patients with MI and multivessel disease.
- Results showed that HBR patients had a higher risk of complications, but those who underwent complete revascularization experienced significantly better outcomes, reducing primary endpoint events.
Impact of pre-admission physical activity on benefits of physiology-guided complete revascularization in older patients with myocardial infarction: insights from the FIRE trial.
Eur J Prev Cardiol
September 2024
Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, Ferrara 44124, Italy.
Aims: The present analysis from the Functional Assessment in Elderly Myocardial Infarction Patients with Multivessel Disease (FIRE) trial aims to explore the significance of pre-admission physical activity and assess whether the benefits of physiology-guided complete revascularization apply consistently to sedentary and active older patients.
Methods And Results: Patients aged 75 years or more with myocardial infarction (MI) and multivessel disease were randomized to receive physiology-guided complete revascularization or culprit-only strategy. The primary outcome was a composite of death, MI, stroke, or any revascularization within a year.
Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study.
Int J Cardiol
July 2023
Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano, Rivoli Infermi Hospital ASLTO3, Rivoli, Turin, Italy.
Article Synopsis
- The resorbable magnesium scaffold (RMS) is being studied for its safety and long-term effectiveness in patients undergoing bioresorbable scaffold implantation, amid conflicting results from earlier research.
- In a multicenter study in Italy, 543 patients were followed for a minimum of one year, with strict criteria for patient selection and RMS implantation techniques.
- Results showed a low occurrence of serious complications at one year, with 3.5% of patients experiencing major adverse events, suggesting that RMS is a safe option that could lead to renewed interest in scaffold technology if further confirmed by randomized trials.